Type 2 diabetes mellitus in older adults: clinical considerations and management

Srikanth Bellary; Ioannis Kyrou; James E. Brown; Clifford J. Bailey

doi:10.1038/s41574-021-00512-2

Type 2 diabetes mellitus in older adults: clinical considerations and management

Srikanth Bellary^*, Ioannis Kyrou, James E. Brown, Clifford J. Bailey

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

The past 50 years have seen a growing ageing population with an increasing prevalence of type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are older adults (aged ≥65 years). Older adults with T2DM present particularly difficult challenges. For example, the accentuated heterogeneity of these patients, the potential presence of multiple comorbidities, the increased susceptibility to hypoglycaemia, the increased dependence on care and the effect of frailty all add to the complexity of managing diabetes mellitus in this age group. In this Review, we offer an update on the key pathophysiological mechanisms associated with T2DM in older people. We then evaluate new evidence relating particularly to the effects of frailty and sarcopenia, the clinical difficulties of age-associated comorbidities, and the implications for existing guidelines and therapeutic options. Our conclusions will focus on the effect of T2DM on an ageing society.

Original language	English
Pages (from-to)	534-548
Number of pages	15
Journal	Nature Reviews Endocrinology
Volume	17
Issue number	9
Early online date	25 Jun 2021
DOIs	https://doi.org/10.1038/s41574-021-00512-2
Publication status	Published - Sept 2021

Bibliographical note

Funding: S.B. has received research grants from The Binding Site Ltd. and Novo Nordisk, UK, Ltd. as well as speaker fees and honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Janssen, Eli Lilly, and Sanofi-Aventis outside of the submitted work. C.J.B. has received personal fees from AstraZeneca, Boehringer Ingelheim, Elcelyx, Lexicon, Poxel, Eli Lilly, Janssen, Merck, Sharpe & Dohme, Novo Nordisk, and Sanofi-Aventis. J.E.B. has received speaker fees from Gilead Biosciences Inc. I.K. has no competing interests to declare.

Keywords

Endocrine system
metabolic diseases
Type 2 diabetes

Access to Document

10.1038/s41574-021-00512-2

Cite this

@article{a3e4db7d224e4db98d5e1b832145bd8f,

title = "Type 2 diabetes mellitus in older adults: clinical considerations and management",

abstract = "The past 50 years have seen a growing ageing population with an increasing prevalence of type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are older adults (aged ≥65 years). Older adults with T2DM present particularly difficult challenges. For example, the accentuated heterogeneity of these patients, the potential presence of multiple comorbidities, the increased susceptibility to hypoglycaemia, the increased dependence on care and the effect of frailty all add to the complexity of managing diabetes mellitus in this age group. In this Review, we offer an update on the key pathophysiological mechanisms associated with T2DM in older people. We then evaluate new evidence relating particularly to the effects of frailty and sarcopenia, the clinical difficulties of age-associated comorbidities, and the implications for existing guidelines and therapeutic options. Our conclusions will focus on the effect of T2DM on an ageing society.",

keywords = "Endocrine system, metabolic diseases, Type 2 diabetes",

author = "Srikanth Bellary and Ioannis Kyrou and Brown, {James E.} and Bailey, {Clifford J.}",

note = "Funding: S.B. has received research grants from The Binding Site Ltd. and Novo Nordisk, UK, Ltd. as well as speaker fees and honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Janssen, Eli Lilly, and Sanofi-Aventis outside of the submitted work. C.J.B. has received personal fees from AstraZeneca, Boehringer Ingelheim, Elcelyx, Lexicon, Poxel, Eli Lilly, Janssen, Merck, Sharpe & Dohme, Novo Nordisk, and Sanofi-Aventis. J.E.B. has received speaker fees from Gilead Biosciences Inc. I.K. has no competing interests to declare. ",

year = "2021",

month = sep,

doi = "10.1038/s41574-021-00512-2",

language = "English",

volume = "17",

pages = "534--548",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Type 2 diabetes mellitus in older adults

T2 - clinical considerations and management

AU - Bellary, Srikanth

AU - Kyrou, Ioannis

AU - Brown, James E.

AU - Bailey, Clifford J.

N1 - Funding: S.B. has received research grants from The Binding Site Ltd. and Novo Nordisk, UK, Ltd. as well as speaker fees and honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Janssen, Eli Lilly, and Sanofi-Aventis outside of the submitted work. C.J.B. has received personal fees from AstraZeneca, Boehringer Ingelheim, Elcelyx, Lexicon, Poxel, Eli Lilly, Janssen, Merck, Sharpe & Dohme, Novo Nordisk, and Sanofi-Aventis. J.E.B. has received speaker fees from Gilead Biosciences Inc. I.K. has no competing interests to declare.

PY - 2021/9

Y1 - 2021/9

N2 - The past 50 years have seen a growing ageing population with an increasing prevalence of type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are older adults (aged ≥65 years). Older adults with T2DM present particularly difficult challenges. For example, the accentuated heterogeneity of these patients, the potential presence of multiple comorbidities, the increased susceptibility to hypoglycaemia, the increased dependence on care and the effect of frailty all add to the complexity of managing diabetes mellitus in this age group. In this Review, we offer an update on the key pathophysiological mechanisms associated with T2DM in older people. We then evaluate new evidence relating particularly to the effects of frailty and sarcopenia, the clinical difficulties of age-associated comorbidities, and the implications for existing guidelines and therapeutic options. Our conclusions will focus on the effect of T2DM on an ageing society.

AB - The past 50 years have seen a growing ageing population with an increasing prevalence of type 2 diabetes mellitus (T2DM); now, nearly half of all individuals with diabetes mellitus are older adults (aged ≥65 years). Older adults with T2DM present particularly difficult challenges. For example, the accentuated heterogeneity of these patients, the potential presence of multiple comorbidities, the increased susceptibility to hypoglycaemia, the increased dependence on care and the effect of frailty all add to the complexity of managing diabetes mellitus in this age group. In this Review, we offer an update on the key pathophysiological mechanisms associated with T2DM in older people. We then evaluate new evidence relating particularly to the effects of frailty and sarcopenia, the clinical difficulties of age-associated comorbidities, and the implications for existing guidelines and therapeutic options. Our conclusions will focus on the effect of T2DM on an ageing society.

KW - Endocrine system

KW - metabolic diseases

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85108838466&partnerID=8YFLogxK

UR - https://www.nature.com/articles/s41574-021-00512-2

U2 - 10.1038/s41574-021-00512-2

DO - 10.1038/s41574-021-00512-2

M3 - Review article

C2 - 34172940

AN - SCOPUS:85108838466

SN - 1759-5029

VL - 17

SP - 534

EP - 548

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

IS - 9

ER -

Type 2 diabetes mellitus in older adults: clinical considerations and management

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this